$CLPT

BURNETT JOSEPH sold $33K of CLPT (indirect holdings)

BURNETT JOSEPH (CEO and President) sold 1,843 indirectly-held shares of ClearPoint Neuro, Inc. (CLPT) at $17.94 on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BURNETT JOSEPH
Published Jun 22, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLPT
Neutral
high confidence
Mentioned
$CLPT
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLPTNeutralLow
01

Why it matters

The newest disclosed fact is the June 17 open-market sale of 1,843 shares by CEO Joseph Burnett under a 10b5-1 plan, with post-sale holdings reported.

02

Market read

Primarily useful for tracking insider activity; likely limited trading impact absent additional company-specific catalysts.

03

What to watch

The sale is indirect and on a pre-arranged plan; without context on total planned volume and prior filings, the signal strength is uncertain.

Relevance 2/10Novelty 3/10Timing: Filed June 22 after the June 17 sale; relevant for monitoring insider-flow sentiment.

Background

The article is an SEC Form 4 insider transaction disclosure for ClearPoint Neuro, Inc. (CLPT).

Company-level read

Ticker impact

$CLPTNeutralHigh confidence
Context

ClearPoint Neuro CEO Joseph Burnett filed a Form 4 selling 1,843 shares at $17.94 on a 10b5-1 plan, reducing holdings to 191,388.

Expected impact

Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 nature.

Evidence & confidence

The filing is a disclosed insider transaction with a stated pre-arranged 10b5-1 plan; there is no accompanying operational, financial, or regulatory development in the text.

Market effects

Minimal—this is company-specific insider transaction data with no sector-wide read-across provided.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with periods of perceived valuation risk; traders may still watch for follow-on selling volume or clustering of insider actions.

Key entities

  • ClearPoint Neuro, Inc.

    Company whose Form 4 insider transaction is disclosed (CLPT).

  • Joseph Burnett

    CEO and President; reported an indirect open-market sale under a 10b5-1 plan.

Related articles

$CLPTMed

ClearPoint Neuro, Inc. (CLPT): Results of Operations and Financial Condition

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 clpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, In